Trials / Completed
CompletedNCT02696967
A Study of CLR325 in Chronic Stable Heart Failure Patients.
A Randomized, Subject and Investigator-blind, Placebo-controlled Study of CLR325 in Chronic Stable Heart Failure Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLR325 | CLR325 Concentrate for solution for infusion |
| OTHER | Placebo | Normal saline |
Timeline
- Start date
- 2016-05-17
- Primary completion
- 2019-01-14
- Completion
- 2019-01-14
- First posted
- 2016-03-02
- Last updated
- 2021-01-05
- Results posted
- 2020-03-04
Locations
11 sites across 5 countries: United States, Belgium, Germany, Netherlands, Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02696967. Inclusion in this directory is not an endorsement.